Skip to main content
. Author manuscript; available in PMC: 2016 Feb 3.
Published in final edited form as: Transplantation. 2010 Sep 15;90(5):540–546. doi: 10.1097/TP.0b013e3181e8dabe

Figure 3. A threshold value of 3.2% for BAL FoxP3+ cells among CD4+ cells is associated with the development of, versus freedom from, BOS.

Figure 3

The composite level of BAL CD4+FoxP3+ percentages was assessed for both the stable patients and the BOS patients prior to BOS development. A threshold level of 3.2% was identified to distinguish the two groups with respect to the subsequent development of BOS.